Angiolite
Coronary sirolimus stent
The DES we trust
Angiolite
Sivasakthi Medical Systems India Private Limited
Coronary Stents
Excellent performance even in compromised situations
Left Main and bifurcation lesions: One of the highest overexpansion capacity for large vessels
6.00 mm
75 µm
Small vessels: Adapted to the need of the arteries with thin struts
Diffuse lesions: new available lengths
44 & 49 mm
Calcified lesions: excellent arterial support
+40%
vs competitors
High quality of healing
TransferWise, the iVascular proprietary technology that provides a homogenous drug elution that translates into lower rates of restenosis and inflammation score.
Our fluoro-acrylate polymer provides an early endothelialization and creates a thromboresistant layer. This mechanism suggest to reduce stent thrombosis.
Angiolite has proven its safety and efficacy in the following clinical trials and registries
ANCHOR Study
Observational, prospective, multicenter study
86.3% Strut coverage
at 3 months
ANGIOLITE Trial
Randomized, non-inferiority, observational, prospective, multicenter trial
0.04mm LLL
at 6 months
RANGO Registry
Prospective, single arm, multicenter observational registry
3.4% TLF
at 2 year